Since CD7 is an early prognostic marker detected at the CP stage, changes in its DNA methylation level, in conjunction to transcript levels, offer a potentially useful predictor of early-stage poor-prognosis CML. This evidence concerns the gene CD7 and chronic myelogenous leukemia, BCR-ABL1 positive.